Literature DB >> 15950655

Lipiodol alters murine uterine dendritic cell populations: a potential mechanism for the fertility-enhancing effect of lipiodol.

Neil Phillip Johnson1, Santwona Bhattu, Angela Wagner, Deborah Adella Blake, Lawrence William Chamley.   

Abstract

OBJECTIVE: To determine whether treatment with lipiodol alters the leukocyte population in the uterus.
DESIGN: Randomized controlled animal study.
SETTING: University research laboratory. ANIMAL(S): Sixty female Swiss white mice at proestrous. INTERVENTION(S): Infusion of the female reproductive tract with lipiodol versus infusion with saline versus sham treatment. MAIN OUTCOME MEASURE(S): Counts of uterine macrophages, dendritic cells, and total leukocytes assessed by immunohistochemistry. RESULT(S): No statistically significant differences were found in the mean number of total leukocytes or macrophages between the three treatment groups. The mean number of CD205+ dendritic cells showed a statistically significant decrease following lipiodol treatment compared with the sham treatment and saline treatment. The mean number of CD1+ dendritic cells showed a statistically significant increase following lipiodol treatment compared with the sham treatment. CONCLUSION(S): Intrauterine lipiodol infusion is associated with a change in the uterine dendritic cell populations in mice. This change may alter the uterine immune response to the fetus, leading to improved fertility.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15950655     DOI: 10.1016/j.fertnstert.2004.11.065

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  7 in total

Review 1.  Tubal flushing for subfertility.

Authors:  Lamiya Mohiyiddeen; Anne Hardiman; Cheryl Fitzgerald; Edward Hughes; Ben Willem J Mol; Neil Johnson; Andrew Watson
Journal:  Cochrane Database Syst Rev       Date:  2015-05-01

2.  Uterine bathing with sonography gel prior to IVF/ICSI-treatment in patients with endometriosis, a multicentre randomised controlled trial.

Authors:  M C I Lier; H Özcan; A M F Schreurs; P M van de Ven; K Dreyer; L E E van der Houwen; N P Johnson; F Vandekerckhove; H R Verhoeve; W Kuchenbecker; B W Mol; C B Lambalk; V Mijatovic
Journal:  Hum Reprod Open       Date:  2020-11-16

Review 3.  Essentiality of Trace Elements in Pregnancy, Fertility, and Gynecologic Cancers-A State-of-the-Art Review.

Authors:  James Curtis Dring; Alicja Forma; Zuzanna Chilimoniuk; Maciej Dobosz; Grzegorz Teresiński; Grzegorz Buszewicz; Jolanta Flieger; Tomasz Cywka; Jacek Januszewski; Jacek Baj
Journal:  Nutrients       Date:  2021-12-31       Impact factor: 5.717

4.  Uterine Cavity Irrigation With Office Hysteroscopy During Ovarian Stimulation for IVF: A Randomized Controlled Trial.

Authors:  Marzieh Ghasemi; Ashraf Aleyasin; Human M Fatemi; Faezeh Ghaemdoust; Mahnaz Shahrakipour
Journal:  Front Endocrinol (Lausanne)       Date:  2022-02-09       Impact factor: 5.555

5.  Fertility Outcome and Safety of Ethiodized Poppy Seed Oil for Hysterosalpingography in 1,053 Infertile Patients: A Real-World Study.

Authors:  Hongjiang Li; Yannan Ren; Jianxiang Yan; Meiling Huang; Bolin Zheng; Xiangmin Luo; Suzhen Huang; Siqing Cai
Journal:  Front Med (Lausanne)       Date:  2022-04-15

6.  Oil-based versus water-based contrast media for hysterosalpingography in infertile women of advanced age, with ovulation disorders or a high risk for tubal pathology: study protocol of a randomized controlled trial (H2Oil2 study).

Authors:  K Rosielle; D Kamphuis; N van Welie; I Roest; A Mozes; E J P van Santbrink; T van de Laar; A B Hooker; A G Huppelschoten; W Li; M Y Bongers; J Stoker; M van Wely; C Koks; C B Lambalk; A Hemingway; B W J Mol; K Dreyer; V Mijatovic
Journal:  BMC Womens Health       Date:  2022-04-18       Impact factor: 2.742

7.  Fertility-enhancing effect of oil-based contrast agents during hysterosalpingography and the variation of this effect within a 3-year follow-up period in infertile patients.

Authors:  Jingyuan Lu; Dan Qi; Wenjian Xu
Journal:  Front Med (Lausanne)       Date:  2022-08-29
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.